MedTrace Logo

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

NCT03440892 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2022-05-04

No results posted yet for this study

Summary

To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

Conditions

Interventions

DRUG

methotrexate

folate antagonist

DRUG

sulfasalazine

Immunomodulatory

DRUG

abatacept

Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)

DRUG

tocilizumab

IL-6 receptor antagonist

DRUG

tofacitinib/baricitinib

JAK inhibitor

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03440892 on ClinicalTrials.gov